You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. CMV Vectored Herpes Simplex Vaccine

    SBC: TOMEGAVAX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The longterm goal of this project is to utilize cytomegalovirus (CMV) vectors in the development of a therapeutic vaccine against herpes simplex virus 2 (HSV-2), the causative agent of genital herpes. HSV-2 is widely prevalent in the population causing recurrent genital lesions and significantly increasing the risk for other sexually transmitted diseases such a ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Topically-delivered Targeted Gene Suppression of Immune Activation in Psoriasis

    SBC: Exicure, Inc.            Topic: NIAMS

    DESCRIPTION (provided by applicant): AuraSense Therapeutics (AST), along with Northwestern University, is applying a recently developed technology using oligonucleotide-functionalized nanoparticles (called spherical nucleic acids or SNAs) to control protein expression. These easily synthesized nanoparticles can have either DNA or RNA shells, and are less than 50 nm in hydrodynamic diameter. SNA co ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Engineering Cytolytic Effectors to Eliminate Virus-Infected and Cancer Cells

    SBC: IMMUVEN, INC.            Topic: NCI

    Project Summary The goal of this STTR grant application is to engineer powerful NK cell-based cytolytic effector cells for therapeutic applications. The cells will combine the selectivity and specificity of T cells and the ability of NK cells to mediate effective cytolytic activity against a wide spectrum of aberrant cells, including those with impaired adhesion properties. To achieve this goal we ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Mucins in the Diagnosis and Prognosis of Pancreatic Diseases

    SBC: Sanguine Diagnostics And Therapeutics, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Due to its asymptomatic nature and lack of methods for early detection, gt 80% of pancreatic cancer (PC) patients present with an unresectable primary tumor with distant metastasis at the time of diagnosis. While the overall 5 year survival rate of pancreatic cancer is dismal, significantly better outcomes have been reported for smaller tumors detected at an e ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Developing Therapeutics That Target RAD51 to Treat Leukemia and Lymphoma

    SBC: Cyteir Therapeutics, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Genomic instability is a hallmark of cancer, yet is underdeveloped as a therapeutic target area The central goal of this program is to develop new cancer therapeutics that target genomic instability as a hallmark of cancer cells, bringing new, cancer-cell selective treatments to the clinical oncology market. Two key challenges in current cancer therapy are mini ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. A Millimeter-wave Tunable Cavity for Ultra-sensitive Solids and Liquids DNP-NMR at Low Budget

    SBC: DOTY SCIENTIFIC, INC.            Topic: NIA

    ? DESCRIPTION (provided by applicant): NMR is probably the most powerful and widely used analytical technique for structure determination and function elucidation of molecules of all types, but it suffers from low sensitivity, particularly for insoluble biological macromolecules. Dynamic Nuclear Polarization (DNP) with Magic Angle Spinning (MAS) has recently demonstrated S/N gains exceeding t ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Developing a Novel eHealth Application for Oral Systemic Issues during Pregnancy

    SBC: InterVision Media            Topic: NIDCR

    DESCRIPTION (provided by applicant): Oral disease is a silent epidemic because of its prevalence and missed prevention opportunities. Evidence has established connections between oral-systemic etiologies, including the effects of periodontal disease (PD), and a range of health outcomes and co-morbidities across the lifecourse (e.g., adverse pregnancy and birth outcomes; early childhood carries; ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Microbial Surrogate Assay for Environmental PAH Exposure

    SBC: ARPHION LTD.            Topic: NIEHS

    DESCRIPTION (provided by applicant): Arphion is a company established to develop noninvasive products that will be used to diagnose, prevent, and treat head and neck and other cancers. 41,000 people are diagnosed with head and neck cancer (HNC) every yearin the United States, with 8,000 deaths. Tens of millions of people in the US are at increased risk for HNC due to exposure to the polycyclic ary ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Rapid Screening Assay for Novel Epigenetic Drugs

    SBC: Nzumbe, Inc.            Topic: NIEHS

    DESCRIPTION (provided by applicant): A hallmark of virtually every cancer is aberrant epigenetic silencing of vital genes required for a normal cell cycle and genome stability (e.g. MLH1, BRCA1, VHL, p16, etc.). Loss of expression of these tumor suppressorgenes plays a critical role in cancer formation and growth. Thus, targeting this root cause of cancer has significant potential to treat and pot ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government